Logo image of NCI

NEO-CONCEPT INTL GROUP HLD-A (NCI) Stock Fundamental Analysis

USA - NASDAQ:NCI - KYG6421C1208 - Common Stock

1.95 USD
-0.03 (-1.52%)
Last: 9/23/2025, 8:00:01 PM
1.82 USD
-0.13 (-6.67%)
Pre-Market: 9/24/2025, 6:20:44 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to NCI. NCI was compared to 48 industry peers in the Textiles, Apparel & Luxury Goods industry. NCI has only an average score on both its financial health and profitability. NCI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

NCI had positive earnings in the past year.
NCI had a positive operating cash flow in the past year.
NCI Yearly Net Income VS EBIT VS OCF VS FCFNCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

NCI has a better Return On Assets (6.99%) than 81.25% of its industry peers.
NCI has a Return On Equity of 16.68%. This is in the better half of the industry: NCI outperforms 72.92% of its industry peers.
NCI's Return On Invested Capital of 10.33% is fine compared to the rest of the industry. NCI outperforms 70.83% of its industry peers.
Industry RankSector Rank
ROA 6.99%
ROE 16.68%
ROIC 10.33%
ROA(3y)13.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NCI Yearly ROA, ROE, ROICNCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

NCI has a Profit Margin of 3.01%. This is comparable to the rest of the industry: NCI outperforms 52.08% of its industry peers.
NCI's Profit Margin has improved in the last couple of years.
NCI has a Operating Margin of 3.83%. This is in the lower half of the industry: NCI underperforms 60.42% of its industry peers.
In the last couple of years the Operating Margin of NCI has grown nicely.
The Gross Margin of NCI (20.90%) is worse than 83.33% of its industry peers.
In the last couple of years the Gross Margin of NCI has grown nicely.
Industry RankSector Rank
OM 3.83%
PM (TTM) 3.01%
GM 20.9%
OM growth 3Y38.21%
OM growth 5YN/A
PM growth 3Y14.72%
PM growth 5YN/A
GM growth 3Y30.72%
GM growth 5YN/A
NCI Yearly Profit, Operating, Gross MarginsNCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 5 10 15 20

More info and screens

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NCI is destroying value.
Compared to 1 year ago, NCI has about the same amount of shares outstanding.
The debt/assets ratio for NCI has been reduced compared to a year ago.
NCI Yearly Shares OutstandingNCI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M 4M
NCI Yearly Total Debt VS Total AssetsNCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.86 indicates that NCI is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.86, NCI is in line with its industry, outperforming 50.00% of the companies in the same industry.
NCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.86
ROIC/WACC0.96
WACC10.81%
NCI Yearly LT Debt VS Equity VS FCFNCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

2.3 Liquidity

NCI has a Current Ratio of 1.84. This is a normal value and indicates that NCI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of NCI (1.84) is comparable to the rest of the industry.
NCI has a Quick Ratio of 1.75. This is a normal value and indicates that NCI is financially healthy and should not expect problems in meeting its short term obligations.
NCI has a better Quick ratio (1.75) than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.75
NCI Yearly Current Assets VS Current LiabilitesNCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 192.30% over the past year.
Measured over the past years, NCI shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.35% on average per year.
NCI shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.91%.
The Revenue has been decreasing by -0.68% on average over the past years.
EPS 1Y (TTM)192.3%
EPS 3Y15.35%
EPS 5YN/A
EPS Q2Q%89.32%
Revenue 1Y (TTM)24.91%
Revenue growth 3Y-0.68%
Revenue growth 5YN/A
Sales Q2Q%35.28%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCI Yearly Revenue VS EstimatesNCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 6.29, the valuation of NCI can be described as very cheap.
Based on the Price/Earnings ratio, NCI is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
NCI's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.41.
Industry RankSector Rank
PE 6.29
Fwd PE N/A
NCI Price Earnings VS Forward Price EarningsNCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NCI is valued cheaply inside the industry as 85.42% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5.59
NCI Per share dataNCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEO-CONCEPT INTL GROUP HLD-A

NASDAQ:NCI (9/23/2025, 8:00:01 PM)

Premarket: 1.82 -0.13 (-6.67%)

1.95

-0.03 (-1.52%)

Chartmill FA Rating
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryTextiles, Apparel & Luxury Goods
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.28%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap7.92M
Analysts60
Price TargetN/A
Short Float %4.59%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.29
Fwd PE N/A
P/S 0.2
P/FCF N/A
P/OCF 143.76
P/B 1.08
P/tB 1.42
EV/EBITDA 5.59
EPS(TTM)0.31
EY15.9%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)0.01
OCFY0.7%
SpS9.98
BVpS1.8
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.99%
ROE 16.68%
ROCE 12.52%
ROIC 10.33%
ROICexc 11.41%
ROICexgc 13.51%
OM 3.83%
PM (TTM) 3.01%
GM 20.9%
FCFM N/A
ROA(3y)13.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.04%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y38.21%
OM growth 5YN/A
PM growth 3Y14.72%
PM growth 5YN/A
GM growth 3Y30.72%
GM growth 5YN/A
F-Score6
Asset Turnover2.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 884.5%
Cap/Sales 6.09%
Interest Coverage 3.64
Cash Conversion 3.01%
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.75
Altman-Z 2.86
F-Score6
WACC10.81%
ROIC/WACC0.96
Cap/Depr(3y)323.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)192.3%
EPS 3Y15.35%
EPS 5YN/A
EPS Q2Q%89.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)24.91%
Revenue growth 3Y-0.68%
Revenue growth 5YN/A
Sales Q2Q%35.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.89%
EBIT growth 3Y37.27%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.87%
OCF growth 3Y-65.32%
OCF growth 5YN/A